EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.93
+0.47 (+3.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close12.46
Open12.55
Bid11.92 x 800
Ask14.97 x 1100
Day's Range12.41 - 13.04
52 Week Range5.14 - 18.55
Volume364,907
Avg. Volume806,704
Market Cap1.174B
Beta (3Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.80
  • Business Wire10 days ago

    Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June. Updated data from the fully enrolled cohort of epithelioid sarcoma patients in the company’s molecularly defined solid tumor program will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Updated data from the fully enrolled cohorts of patients with follicular lymphoma, both with and without EZH2 activating mutations, will be reported at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)
    Insider Monkey17 days ago

    Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)

    The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]

  • Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
    Zacks21 days ago

    Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press21 days ago

    Epizyme: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...

  • Business Wire21 days ago

    Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results

    Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively

  • If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today
    Simply Wall St.last month

    If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today

    It is a pleasure to report that the Epizyme, Inc. (NASDAQ:EPZM) is up 39% in the last quarter. But over the last half decade, the stock has not performed well. In fact, the share price is down 39%, which falls well short o...

  • Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire2 months ago

    Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering price of each share of Series A stock was $115.00. The aggregate gross proceeds to Epizyme from the offerings, before deducting underwriting discounts and offering expenses, are $172.50 million.

  • Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?
    Simply Wall St.3 months ago

    Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?

    Rob Bazemore has been the CEO of Epizyme, Inc. (NASDAQ:EPZM) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...

  • Business Wire3 months ago

    Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deducting underwriting discounts and offering expenses. The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.

  • Business Wire3 months ago

    Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.

  • Business Wire3 months ago

    Epizyme Announces Presentations at Upcoming March Investor Conferences

    Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March inv

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT

    Q4 2018 Epizyme Inc Earnings Call

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4
    Zacks3 months ago

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4

    Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2018.

  • Business Wire3 months ago

    Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019

  • Business Wire3 months ago

    Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

    Fourth Quarter and Full-Year 2018 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2018 financial results and other business highlights at 8:30 a.m. ET on Tuesday, February 26, 2019. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 1088195.

  • 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
    Zacks3 months ago

    5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

    Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
    Zacks5 months ago

    Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

    Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

  • Why Epizyme Stock Rose ~33% on January 4
    Market Realist5 months ago

    Why Epizyme Stock Rose ~33% on January 4

    Why Epizyme Stock Rose ~32% on January 4 ## Stock performance On January 4, Epizyme (EPZM) stock closed at $7.94, which represents ~32.78% growth from its prior close of $5.98 on January 3, 2019. On January 3, Epizyme stock fell 10.34% to reach $5.98 from its prior-day closing price of $6.67 on January 2. Epizyme stock fell from $12.55 at the close of market on December 29, 2017, to reach $6.16 on December 31, 2018, which was a ~51% decline in 2018. Epizyme’s price on January 4 is ~63% below its 52-week high of $21.4 on March 13, 2018. The company hit its 52-week low of $5.14 on December 24, 2018. ## Reason for stock price rise On January 4, Epizyme announced that it found a path for accelerated approval by the US FDA (Food and Drug Administration) of its investigational drug tazemetostat for the treatment of individuals with relapsed or refractory follicular lymphoma (or FL) who may be with or without EZH2 activating mutations. Epizyme already conducted a meeting with the FDA to discuss the FL registration strategy with the present patient population in the company’s ongoing phase 2 trial. After discussion with the FDA, the company specified the registration strategy for tazemetostat. The company can register patients in both types of EZH2 mutation and patients with wild-type FL with disease progression after two or more lines of therapy. Epizyme expects to submit an NDA (new drug application) to the FDA for the said indications by the fourth quarter of 2019. Epizyme already completed the enrollment of the phase 2 trial for the evaluation of safety and efficacy of tazemetostat for the said indications. Epizyme also anticipates submitting its first NDA to the FDA for tazemetostat for the treatment of individuals with epithelioid sarcoma under accelerated approval pathway in the second quarter of 2019. Epizyme has plans to initiate clinical trials for label expansion of tazemetostat and also evaluate the drug along with other combination therapies. Epizyme sees potential in the drug for the treatment of multiple cancer types. The company plans to initiate the study of tazemetostat for small-cell lung cancer, triple-negative breast cancer, ovarian cancer, and castration-resistant prostate cancer by the second half of 2019. ## Analysts’ recommendations Of the ten analysts tracking Epizyme in January 2019, four of them recommended a “strong buy,” while another four analysts recommended a “buy” rating. Two analysts recommended a “hold” rating for Epizyme in January 2019. The company had a consensus 12-month target price of $19.44, which represents a ~144.84% return on investment over the next 12 months.

  • Why GameStop, Novavax, and Epizyme Jumped Today
    Motley Fool5 months ago

    Why GameStop, Novavax, and Epizyme Jumped Today

    It was a great day for the overall market. Find out why these stocks stood out.

  • Here's Why Epizyme's Shares Are Surging 19.6% Higher Today
    Motley Fool5 months ago

    Here's Why Epizyme's Shares Are Surging 19.6% Higher Today

    A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.

  • ACCESSWIRE5 months ago

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • Business Wire5 months ago

    Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations. The company recently conducted a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss the FL registration strategy based on the current patient population in its ongoing Phase 2 clinical trial.

  • Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?
    Insider Monkey5 months ago

    Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?

    “October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]